Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy

NCT07534319 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-04-16

No results posted yet for this study

Summary

Introduction:

Endovascular thrombectomy (EVT) is an effective treatment strategy to mitigate the ischemic tissue damage caused by the acute cerebral large-vessel occlusion. However, in clinical practice, nearly half of the patients do not experience adequate neurological improvement despite successful recanalization - a phenomenon termed reperfusion failure or clinically ineffective reperfusion. Given the clinical relevance of this phenomenon and the absence of a standardized imaging diagnostic method to identify it, our project aims to explore the potential role of blood oxygenation-level dependent cerebrovascular reactivity (BOLD-CVR) as novel imaging biomarker for studying reperfusion failure.

Study population:

Adult patients with acute ischemic stroke of the ICA, MCA or with tandem occlusion who have undergone a successful recanalization, described as mTICI score ≥2b.

Objective(s):

Primary objective: to longitudinally observe blood flow changes derived from BOLD-CVR imaging following successful endovascular thrombectomy in patients with large-vessel occlusion acute ischemic stroke (LVO-AIS) during the early post-treatment phase and assess their association with clinical outcome 90 days post-EVT.

Secondary objective: to compare BOLD-CVR findings with those obtained from the clinical standard dynamic susceptibility contrast (DSC) MR perfusion imaging acquired in the same examination session as well as other imaging techniques included in the standard post-treatment imaging protocol at our institution.

Outcomes:

Clinical outcomes:

* 90-day functional outcome.
* Functional outcome at hospital discharge.
* Neurological deterioration during hospitalization.
* Radiologically confirmed haemorrhagic transformation within the reperfused tissue.
* Radiologically confirmed infarct lesion progression within the reperfused tissue.
* Additionally, DSC MR perfusion imaging parameters and other standard hemodynamic imaging parameters will be considered as imaging outcomes

Study design:

Single-center prospective observational cohort study

Measurements and procedures:

Included patients will undergo a total of 3 BOLD-CVR examinations: 72 hours, 7 days, and 90 days after EVT. Participation in the final examination will mark the end of the subject's involvement in the study. Clinical outcomes will be prospectively collected as per established institutional patient management protocols: during hospitalization, at discharge, and at the cerebrovascular outpatient clinic at 3 months.

Number of Participants:

Target sample size: 100 patients

Given the observational study design and exploratory nature of this project, no sample size calculation can be performed. The provided target sample size (N = 100) has been estimated considering the inclusion of as many consecutive subjects as possible.

Study period: 2.5 years The investigators aim to enroll a target sample size of 100 patients over a period of 2.5 years. This translates to an inclusion of 3-4 patients per month, with the last three months allocated for the follow-up of the last included patients.

Study Centre:

Clinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich

Statistical Considerations:

The association between BOLD-CVR findings and clinical outcomes will be investigated using regression analyses.

Conditions

  • Acute Cerebrovascular Accident
  • Thrombectomy
  • Cerebral Revascularization
  • No Reflow Phenomenon

Interventions

OTHER

No planned intervention

No planned intervention

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Jorn Fierstra, Prof Dr. med., PhD · University of Zurich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2027-09-01
Completion
2027-12-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07534319 on ClinicalTrials.gov